Genentech Raptiva To Undergo 5,000-Patient Postmarketing Safety Study
Genentech will conduct a 5,000-patient study of the incidence of adverse events associated with Raptiva (efalizumab) as a condition of FDA approval of the psoriasis treatment
Genentech will conduct a 5,000-patient study of the incidence of adverse events associated with Raptiva (efalizumab) as a condition of FDA approval of the psoriasis treatment